All In Biotech

Drug Trial Radar · NCT04181788

Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE PHARMACOKINETICS, SAFETY, EFFICACY, AND PHARMACODYNAMICS OF PF-06801591 (PD-1 INHIBITOR) IN PARTICIPANTS WITH ADVANCED MALIGNANCIES

Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 155 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

155

Actual

Start

Mar 18, 2020

Primary completion

Mar 3, 2022

Study completion May 13, 2026

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Nov 29, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1b/2 protocol to evaluate pharmacokinetics, safety, efficacy, and pharmacodynamics of PF-06801591, a programmed death-1(PD-1) antagonist monoclonal antibody (mAb) in participants with advanced malignancies. This study consists of 2 parts: Phase 1b part (dose escalation and dose expansion) in patients with advanced malignancies in Asia and a global Phase 2 part in non small cell lung cancer (NSCLC) patients.

Conditions

  • Advanced Malignancies
  • Non-small-cell Lung Cancer

Interventions

  • PF-06801591Drug

    A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PDL1/ PD-L2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT)Time frame: Phase 1b: at the end of cycle 1 (28 days) for the PF-06801591 300 mg SC Q4W arms, and (42 days) for the PF-06801591 600 mg SC Q6W arms
  2. Phase 2: AUCτ of PF-06801591 at Steady StateTime frame: Phase 2: Cycle 4 Day 1, 8, 15, 22 and Cycle 5 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1, 8, 15, 29 and Cycle 4 Day 1 for the PF-06801591 600 mg SC Q6W arm
  3. Phase 2: Ctrough of PF-06801591 at Steady State, at Week 12Time frame: Phase 2: Cycle 4 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1 for the PF-06801591 600 mg SC Q6W arm

Locations

49 sites in 6 countries. Site status is shown where the registry gives one.

  • Beijing Cancer hospital

    Beijing, Beijing Municipality, China

  • Chongqing Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China

  • Huashan Hospital Affiliated to Fudan University

    Shanghai, Shanghai Municipality, China

  • National Cancer Center Hospital

    Chuo-ku, Tokyo, Japan

  • Evimed Llc

    Chelyabinsk, Russia

  • Chelyabinsk Regional Clinical Centre of Oncology and Nuclear Medicine

    Chelyabinsk, Russia

  • Ars Medika Center, LLC

    Kaliningrad, Russia

  • GBUZ Regional Clinical Hospital of Kaliningrad region

    Kaliningrad, Russia

  • Enlimed Llc

    Kopeysk, Russia

  • Orenburg Regional Clinical Oncological Dispensary

    Orenburg, Russia

  • Russian Scientific Center For Radiology and Surgical Technologies

    Pesochny, Russia

  • LLC Medical Center "Magnit"

    Saint Petersburg, Russia

  • Llc "Mss"

    Saint Petersburg, Russia

  • North-West Medical Center

    Saint Petersburg, Russia

  • Road clinical clinic of JSC "RZD"

    Saint Petersburg, Russia

  • NS HI "Road Clinical Hospital of JSC "Russian Railways""

    Saint Petersburg, Russia

  • Private Healthcare Institution "Clinical Hospital "RZD-Medicine" of St. Petersburg

    Saint Petersburg, Russia

  • LLC "Diagnostic center "Energo"

    Saint Petersburg, Russia

  • Medical University REAVIZ

    Samara, Russia

  • Medical University REAVIZ

    Samara, Russia

  • Russian Research Centre for Radiology and Surgical Technologies

    Saint Petersburg, Pesochny, Russia

  • Private Medical Institution "Euromedservice"

    Pushkin, Sankt-Peterburg, Russia

  • Klinika UZI 4D, LLC

    Pyatigorsk, Stavropol Kray, Russia

  • State budgetary institution of healthcare of Yaroslavl region "Clinical oncology hospital"

    Yaroslavl, Yaroslavl Oblast, Russia

  • Gachon University Gil Medical Center

    Incheon, South Korea

  • Severance Hospital, Yonsei Univ. Health System

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • Communal Non-profit Enterprise City Clinical Hospital #4 of Dnipro City Council

    Dnipro, Ukraine

  • LLC "AR DI PI Ukraine"

    Dnipro, Ukraine

  • Llc "Mdc Expert"

    Dnipro, Ukraine

  • Municipal Non-profit Enterprise "SubCarpathian Clinical Oncological Centre of Ivano-Frankivsk RC"

    Ivano-Frankivsk, Ukraine

  • Private Enterprise of Private Manufacturing Company "Acinus", Medical and Diagnostic Center

    Kropyvnytskyi, Ukraine

  • Medical centre "Verum" Limited Liability Company

    Kyiv, Ukraine

  • Vita Сom LLC

    Kyiv, Ukraine

  • The State Institution "Romodanov Neurosurgery Institute,

    Kyiv, Ukraine

  • Llc Medical Centre

    Odesa, Ukraine

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.